TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04321395
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
Study: NCT06070571
Drug: Yarrow and moringa mixture
Normalized name: YARROW
DrugBank: Morin (DB16770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: yarrow and moringa mixture nano particles loaded on buccal film
Study: NCT04888741
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVHD prophylaxis
Study: NCT04888741
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunosuppressant
Study: NCT04888741
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: immunosuppressant
Study: NCT04888741
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: immunosuppressant
Study: NCT06136546
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion of infliximab
Study: NCT06798246
Drug: ADC
Normalized name: 7-ADCA
DrugBank: 7-Aminodesacetoxycephalosporanic acid (DB14107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC drug like RC48
Study: NCT06798246
Drug: Chemotherapy combined with immunotherapy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy combined with immunotherapy
Study: NCT01724580
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT06234345
Drug: Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants randomized to this group will receive 1 capsule per inhalation twice a day
Study: NCT05480774
Drug: KRG hard capsule
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was given orally 2 KRG hard capsules/day for 12 weeks
Study: NCT06415851
Drug: mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
Study: NCT06414018
Drug: Alfentanil
Normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alfentanil 10ug/kg is used for anesthesia induction
Study: NCT06005818
Drug: Pembrolizumab injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 antibody
Study: NCT04650854
Drug: Rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study: NCT06772818
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05038904
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg oral capsule
Study: NCT05907902
Drug: Aspirin Enteric-coated Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose aspirin 100 mg once daily (one 100mg tablet).
Study: NCT05911399
Drug: Tiratricol
Normalized name: tiratricol
DrugBank: Tiratricol (DB03604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
Study: NCT05014412
Drug: Elranatamab
Normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT03912350
Drug: Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
Study: NCT05180097
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 IV, 30 mins D1, D8
Study: NCT05180097
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg daily PO, D1-D4
Study: NCT05180097
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 IV, 1 hour, D1
Study: NCT05180097
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg IV, 30 mins, Q21 days
Study: NCT05180097
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg IV, 30 mins, Q 21 days
Study: NCT05103605
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single arm treated by osimertinib
Study: NCT04856982
Drug: Tofersen
Normalized name: Tofersen
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05321160
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
Study: NCT05321160
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% sevoflurane for induction and 2-4% sevoflurane for maintain
Study: NCT06477146
Drug: Milk thistle (MT)
Normalized name: Milk thistle
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
Study: NCT06397313
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
Study: NCT05615844
Drug: Antibiotic Cement Bead Pouch
Normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
Study: NCT05146739
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and IT
Study: NCT05146739
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05146739
Drug: Uproleselan
Normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06109779
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilvegostomig IV (intravenous) Q3W
Study: NCT06460987
Drug: Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels
Study: NCT05512364
Drug: Elacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg QD orally on a continuous dosing schedule
Study: NCT05512364
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg QD orally on a continuous dosing schedule
Study: NCT05512364
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg QD orally on a continuous dosing schedule
Study: NCT05512364
Drug: Anastrozole 1mg
Normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg QD orally on a continuous dosing schedule
Study: NCT05512364
Drug: Exemestane 25 MG
Normalized name: exemestane 25 MG
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg QD orally on a continuous dosing schedule
Study: NCT06109779
Drug: Gemcitabine/Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
Study: NCT06109779
Drug: S-1 [Tegafur/Oteracil/gimeracil]
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Study: NCT05398679
Drug: Cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefaclor intravenous 2 gr/day
Study: NCT05398679
Drug: Ciprofloxacin Tablets
Normalized name: Ciprofloxacin Tablets
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500-750 mg/12 hrs (maximum 3g x day)
Study: NCT05398679
Drug: Ciprofloxacin Injection
Normalized name: ciprofloxacin Injection
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg/day maximum dose IV
Study: NCT05398679
Drug: Dicloxacillin Oral Capsule
Normalized name: dicloxacillin Oral Capsule
DrugBank: Dicloxacillin (DB00485)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g/8 hours (maximum 4 gr day)
Study: NCT05398679
Drug: Dicloxacillin
Normalized name: Dicloxacillin
DrugBank: Dicloxacillin (DB00485)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g/8 hours (maximum 4 g x day) IV
Study: NCT05398679
Drug: Fusidic Acid Only Product in Oral Dose Form
Normalized name: Fusidic acid only product in oral dose form
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,750g/12 hours (maximum 1,5 g x day)
Study: NCT05398679
Drug: Fusidic Acid Only Product in Parenteral Dose Form
Normalized name: Fusidic acid only product in parenteral dose form
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,75 g/12 hours (maximum 1,5 g x day)
Study: NCT05398679
Drug: Levofloxacin Oral Tablet
Normalized name: levofloxacin Oral Tablet
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g/12-24hours (maximum 1 g x day)
Study: NCT05398679
Drug: Levofloxacin Injection
Normalized name: levofloxacin Injection
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g/12-24hours (maximum 1 g x day)
Study: NCT05398679
Drug: Linezolid Oral Tablet
Normalized name: linezolid Oral Tablet
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,6 g/12 hours (maximum 1200 mg x day)
Study: NCT05398679
Drug: Linezolid Injectable Product
Normalized name: linezolid Injectable Product
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,6 g/12 hours (maximum 1200 mg x day)
Study: NCT05398679
Drug: Moxifloxacin tablet
Normalized name: Moxifloxacin Tablets
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,4 g/day (maximum 400 mg x day)
Study: NCT05398679
Drug: Moxifloxacin Injectable Product
Normalized name: moxifloxacin Injectable Product
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,4 g/day (maximum 400 mg x day)
Study: NCT05398679
Drug: Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]
Normalized name: sulfamethoxazole / trimethoprim Oral Tablet [Bactrim]
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
Study: NCT05398679
Drug: Sulfamethoxazole / Trimethoprim Injectable Product
Normalized name: sulfamethoxazole / trimethoprim Injectable Product
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
Study: NCT05398679
Drug: Tedizolid Oral Tablet
Normalized name: tedizolid Oral Tablet
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg tedizolid (maximum x day)
Study: NCT05398679
Drug: Tedizolid Injection
Normalized name: tedizolid Injection
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg (maximum x day)
Study: NCT05398679
Drug: Amoxicillin Capsules
Normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gr/6 hours (4 g x day)
Study: NCT05398679
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gr/6 hours (4 g x day) Intravenous
Study: NCT05398679
Drug: Cefaclor Capsules
Normalized name: Cefaclor Capsules
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 gr/day
Study: NCT05935761
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
Study: NCT05935761
Drug: DHEA
Normalized name: DHEA
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
Study: NCT05976230
Drug: Entresto
Normalized name: Entresto
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT04987320
Drug: Olpasiran
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06408181
Drug: Aspirin 162 mg
Normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Study: NCT06408181
Drug: Aspirin 81mg
Normalized name: ASPIRIN 81MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Study: NCT05087992
Drug: BI 905711
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 905711
Study: NCT05087992
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab
Study: NCT04266730
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
Study: NCT05715606
Drug: Metabolically Armed CD19 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
Study: NCT05899010
Drug: Vaginal progesterone 600mg daily
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Study: NCT05899010
Drug: Vaginal progesterone 800mg daily
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Study: NCT05302284
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0 mg/kg IV every 2 weeks
Study: NCT05302284
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg IV every 2 weeks
Study: NCT05302284
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
Study: NCT05302284
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70mg/m2 IV infusion on Day 1 of every 3 week cycle
Study: NCT05302284
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=4.5, IV infusion on Day 1 of every 3 week cycle
Study: NCT01931085
Drug: Triclabendazole
Normalized name: TRICLABENDAZOLE
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclabendazole (10 mg/kg body-weight as a single dose).
Study: NCT05060263
Drug: HOT-1030
Normalized name: Hot pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Study: NCT04807192
Drug: CMP-001
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
Study: NCT06551246
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to randomization.
Study: NCT06551246
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to randomization.
Study: NCT06468280
Drug: PD-1 Monoclonal Antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
Study: NCT05550558
Drug: Anlotinib + Camrelizumab
Normalized name: Camrelizumab
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib PO plus Camrelizumab IV
Study: NCT05758922
Drug: AZ-3102 (Dose 1)
Normalized name: AZ-3102
DrugBank: AZ-3102 (DB18502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT05758922
Drug: AZ-3102 (Dose 2)
Normalized name: AZ-3102
DrugBank: AZ-3102 (DB18502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT06111014
Drug: Latozinemab
Normalized name: Latozinemab
DrugBank: Latozinemab (DB16978)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
Study: NCT05869955
Drug: CC-97540
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05869955
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05869955
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05106296
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Study: NCT05106296
Drug: Indoximod
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
Study: NCT05106296
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.